PTK2 and lung cancer: The present study clearly demonstrates that oridonin can inhibit H1688 cell proliferation; furthermore, the intraperitoneal administration of oridonin at a dosage of 5 mg/kg caused a significant decline in tumour volume in lung cancer xenograft‐bearing nude mice associated with suppression of the FAK signalling pathway.